Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00009204
Status:
COMPLETED
Last Update Posted:
2017-06-16
First Post:
2001-01-23
Brief Title:
Serotonergic Pharmacotherapy for Agitation of Dementia
Sponsor:
Bruce Pollock
Organization:
University of Pittsburgh
Study Overview
Official Title:
Serotonergic Pharmacotherapy for Agitation of Dementia
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SPAD
Brief Summary:
This study is a randomized double-blind placebo-controlled fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia allowing them to be maintained in the community for greater periods of time
Detailed Description:
The principal investigator is conducting an inpatient study at Western Psychiatric Institute and Clinic involving two medications for treatment of emotional and behavioral disturbances that may accompany dementia In this study 112 patients will be enrolled for up to 17 days in order to investigate the safety and effectiveness of both medications Forty-two of these patients will be given a recently FDA-approved antidepressant medication called citalopram and 42 will receive one of our current usual antipsychotic medications called perphenazine An additional 28 patients will be given non-active placebo capsules Which treatment a patient is given during the study will be determined by chance Findings from this investigation may directly lead to the improvement of symptoms such as agitation hostility suspiciousness hallucinations and unusual thoughts Improved treatment of problematic behaviors and a decrease in medication-associated side effects would enable dementia patients to be cared for in their home environments for longer periods of time
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DSIR GT-GP | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH059666-01 |
| R01MH059666-01 | NIH | None | None |
| IA0014 | None | None | None |